Mineralys Therapeutics, Inc. (Nasdaq: MLYS) announced an upsized underwritten public offering of 9,803,921 shares of its common stock at $25.50 per share, totaling approximately $250.0 million in gross proceeds. The offering, expected to close on September 4, 2025, will fund the development of lorundrostat and other activities. BofA Securities, Evercore ISI, Goldman Sachs & Co. LLC, Stifel, and Wells Fargo Securities are the joint book-running managers for the offering. Mineralys intends to use the net proceeds for clinical development, research, manufacturing, pre-commercialization activities, and general corporate purposes.

Mineralys Therapeutics, a biopharmaceutical company focused on hypertension and related diseases, is offering 9,803,921 shares of common stock at $25.50 per share, aiming to raise $250.0 million. The underwriters have a 30-day option to purchase an additional 1,470,588 shares. The company plans to use the proceeds for the development of lorundrostat and pre-commercialization activities. BofA Securities, Evercore ISI, Goldman Sachs & Co. LLC, Stifel, and Wells Fargo Securities are managing the offering. Mineralys’ securities are offered under a shelf registration statement filed with the SEC, and the offering is expected to close on September 4, 2025.

Mineralys Therapeutics, Inc. (Nasdaq: MLYS) is a clinical-stage biopharmaceutical company focusing on developing treatments for hypertension and related conditions. Their initial product candidate, lorundrostat, is an oral aldosterone synthase inhibitor. Mineralys was founded by Catalys Pacific and is based in Radnor, Pennsylvania. The company’s public offering of 9,803,921 shares of common stock at $25.50 per share is expected to raise approximately $250.0 million in gross proceeds, with plans to use the funds for clinical development, research, and working capital.

Read more at GlobeNewswire: Mineralys Therapeutics Announces Pricing of Upsized $250.0